07:44 AM EDT, 04/01/2026 (MT Newswires) -- Alkermes ( ALKS ) said Wednesday that it initiated a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy.

The program consists of three 12-week phase 3 studies evaluating once-daily and split-dose regimens of alixorexton, and will enroll patients across sites in North America, Asia Pacific and Europe, the company said.

The primary endpoint of each study is whether participants taking alixorexton experience an increase in wakefulness compared to participants taking placebo, Alkermes ( ALKS ) said.

The company's shares were up 1.9% in Wednesday premarket activity.